Plasma Exosome RNA to Diagnose Prostate Cancer
Launched by XIJING HOSPITAL · Sep 17, 2024
Trial Information
Current as of August 20, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Blood prostate-specific antigen PSA\>4ng/dl;
- • 2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging, and PSMA PET/CT examination.
- • 3. The patient is willing to undergo prostate biopsy.
- Exclusion Criteria:
- • 1. Previous diagnosis of prostate cancer through prostate biopsy;
- • 2. History of other malignant tumors in the past two years;
- • 3. According to the research physician\'s judgment, serious complications may occur and affect the normal conduct of the experiment
About Xijing Hospital
Xijing Hospital, a prominent medical institution affiliated with the Fourth Military Medical University in Xi'an, China, is dedicated to advancing healthcare through innovative clinical research. Renowned for its comprehensive range of medical services and expertise in various specialties, Xijing Hospital actively sponsors clinical trials aimed at evaluating new therapies, improving patient outcomes, and contributing to scientific knowledge. With a commitment to ethical standards and patient safety, the hospital fosters collaboration among multidisciplinary teams to drive forward the development of effective treatment options that address critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xian, Shaanxi, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported